Search

The role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes in cancer patients treated with immune checkpoint inhibitors(ICI)Background Although immune checkpoint inhibitors (ICI) have changed the therapeutic scheme for multiple cancers, only a subset of patients experiences durable benefit. As current tumor markers such as PD-L1 show limited reliability in predicting clinical outcomes, we have explored the predictive role of markers representative of the host immune response on a systemic level present in the circulating proteome. Mass spectrometry allows for analysis of the proteome without the specific identification of individual proteins and protein isoforms. Here, we analyzed the most recent studies using mass spectrometry-based serum proteomics in predicting response to ICI treatment. Method A systematic literature search on Pubmed and major oncology scientific meetings was conducted up to November 18, 2020. Result Classifier algorithms trained with data sets from advanced stages of lung cancer (Primary Immune Response, Host Immune Classifier) and melanoma (BDX008, Immune Checkpoint Blockade) were used to stratify patients into groups with favorable and unfavorable treatment outcome. Patients with unfavorable predictive markers had worse prognosis when treated with ICI-single agent therapy. For patients treated with ICI alone or with chemotherapy as frontline or beyond, mass spectrometry-based serum proteomic signatures were shown to be a reliable predictive marker for survival outcomes (hazard ratios 0.15-0.5) independent of PD-L1 expression level. Conclusion Mass spectrometry-based serum proteomic tests reliably identify patients expected to have a worse prognosis. These patients can benefit from frontline aggressive treatment strategy combining ICI and chemotherapy rather than the standard of care ICI monotherapy. Cancer type Advanced stage NSCLCTreatmentLine of therapyClassifiernumber of patients included (n)number of patients in each classifier, n(%)Survival outcome (OS, month)HR [95%CI]referenceAdvanced stage NSCLCImmunotherapy (nivolumab)2nd linePIR116Not resistant75 (65%)17.30.48 [0.30-0.77], p=0.002Mirte Muller, et al.Resistant41(35%)6.0Sensitive32 (28%)11.10.58 [0.38-0.87], p=0.009Not sensitive84 (72%)4.3Immunotherapy ± ChemotherapyAll lines First line single agent immunotherapy (pembrolizumab) First line Combination (immunotherapy/chemotherapy) All lineHIC284Hot196 (69%)Not reached0.38 [0.27-0.53], p Citation Format: Yoonhee Choi, Jin Young Hwang, Won Kyung Hur, Myungwoo Nam, Leeseul Kim, Yeun Ho Lee, William Cheng, Eugene Kim, Emma Yu, Chan Mi Jung, William Han Bae, Young Kwang Chae. The role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes in cancer patients treated with immune check point inhibitors (ICI) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 673.

Background: Immune checkpoint inhibitor (ICI) treatment became the new treatment paradigm of a wide spectrum of cancers in the last decade. However, overcoming unresponsiveness to ICI remains an important high unmet need in the field of immuno-oncology. It is unclear whether another ICI can be an effective treatment option in patients with tumors refractory to combinatorial immunotherapy. Here we describe a case in whom a significant response to a PD-L1 inhibitor was demonstrated when used concurrently with radiation therapy. Notably, this patient was found to be unresponsive to the combined ICI treatment of PD-1 and CTLA-4 inhibitors. Case Presentation: A 42 y.o. male patient who presented with urinary frequency and hematospermia was diagnosed with stage IV small cell neuroendocrine cancer of prostate gland with osseous metastasis. He was treated with cisplatin plus etoposide for 4 cycles and was subsequently treated with topotecan for 4 cycles given progression of disease (PD). He was given the combination of ipilimumab and nivolumab after another PD. Treatment was discontinued 5 months later due to a lack of response. Two months later, the patient received radiation therapy: 3000 cGy to the prostate and lower pelvis and palliative radiation therapy to the left femur. The patient subsequently underwent multiple lines of treatment with no satisfactory response. Follow up imaging test was concerning for progression with new liver and lung lesions. The treatment was switched to atezolizumab and nab-paclitaxel combination regimen. Concurrently, the patient had stereotactic ablative radiotherapy (4000 cGy) to pelvic region, paraspinal region and para-aortic LNs. Repeated imaging test after two months of the treatment showed an increase in pulmonary nodule size and the treatment was continued despite PD. The repeated scan after 6 weeks revealed an exceptional response that was close to resolution of the metastasized lesion in the liver and significant decrease in size of pulmonary metastatic lesions. Conclusion:This case illustrates the abscopal effect of targeted radiation treatment when coupled with immunotherapy. Exceptional responses seen in non-radiated lesions including lungs and liver after radiation to pelvic lymph nodes while on PD-L1 inhibitors corroborates the concept of synergistic effect of radiation and immunotherapy. Intriguingly, this concurrent treatment approach maximizing the abscopal effect was effective in this case where combinatorial immunotherapy with nivolumab and ipilimumab was ineffective. Future clinical trials are warranted to validate these findings in a more systematic fashion. Citation Format: Leeseul Kim, William Cheng, Yeun Ho Lee, Myungwoo Nam, Won Kyung Hur, Jin Young Hwang, Yoonhee Choi, William H Bae, Cyra Y. Kang, Heayoon Shauna Cho, Emma Yu, Chan Mi Jung, Eugene Kim, Christmann Low, Young Kwang Chae. Exceptional response to PD-L1 inhibitor after radiation therapy in a patient with small cell neuroendocrine tumor of the prostate gland refractory to combination treatment with PD-1 and CTLA-4 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 678.

We aimed to understand how TGF-β signaling pathway related gene mutation affects the tumor neoantigen burden and immune landscape in uterine corpus endometrial carcinoma (UCEC). cBioPortal was queried to obtain the UCEC The Cancer Genome Atlas (TCGA) cohort data (521 patients). TGF-β signaling pathway related gene mutation was defined as genetic variances in TGFBR1, TGFBR2, ACVR2A, ACVR1B, SMAD2, SMAD3, or SMAD4. The neoantigen counts were predicted using CloudNeo pipeline. CIBERSORT was used to predict tumor-infiltrating immune cells. In 521 UCEC patients, 124 had mutations in TGF-β signaling pathway related genes. These tumors with the mutations had significantly higher neoantigen counts, mutation counts, and cytolytic scores (a geometric mean of mRNA expression of perforin and granzyme), and a trend towards higher PD-L1 expression level (Table 1). When subdivided by molecular subtypes, similar patterns were seen in most groups. TGF-β signaling pathway gene mutation was significantly associated with tumor tissue infiltration by CD8 T cells (18.3% vs 10.5%; p< 0.05), active CD4 memory T cells(13.0% vs 7.5%; p Immune landscape of endometrial carcinoma according to TGF-β pathway related gene mutationnumber of valuesneoantigenmutation countcytolytic scorePD-L1 expressionAll521166.1964.5189.914.1TGF-β pathway related gene nonmutated39652.3219.415813.4TGF-β pathway related gene mutated124528.4**3350.0**293.2*16.3POLEmutAll85741.04925268.619.0nonmutated28158.9941.6183.517.7mutated571027.0**6881.0**310.4*19.6MSI-HAll167297.51455.0251.814.8nonmutated99157.1539.5207.714.7mutated68501.9**2787.0**315.915.0P53abnAll192134.7904.1202.616.8nonmutated14820.390.8142.215.6mutated44519.3**3640.0**407.218.5NSMPAll16111.5254.9131.59.7nonmutated15411.554.6133.39.6mutated712.960.491.612.1Values are expressed as mean.*p Citation Format: William H. Bae, Jin Young Hwang, Won Kyung Hur, Myungwoo Nam, Yoonhee Choi, Leeseul Kim, Yeun Ho Lee, William Cheng, Eugene Kim, Emma Yu, Chan Mi Jung, Heayoon S. Cho, Jeff Chuang, Victor Wang, Young Kwang Chae. Immune landscape of endometrial carcinoma and its association with neoantigen landscape and TGF-β signaling pathway related genes mutation status [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 451.

Background: Within serous ovarian cancer (SOC), high-grade serous carcinoma (HGSC) demonstrates a worse prognosis compared to low-grade serous carcinoma (LGSC). Molecular analysis of SOC has revealed a distinct pattern of mutations found between the two pathologic subtypes, with TP53 as the main driver for HGSC. We analyzed the neoantigen and immune landscape of different SOC subtypes according to pathological grades and mutation status. Methods: The analysis was done using the SOC cohort of The Cancer Genome Atlas (TCGA). The neoantigen prediction was done through the CloudNeo pipeline. CIBERSORT was applied to derive the tumor-infiltrating immune cells. Patients were grouped by their pathological grades (high vs. low) and the molecular features (type 1 vs. 2). For further subgroup analysis, high-grade samples were stratified by their TP53 mutation status. Results: Among 585 SOC patients, a subset of 254 patients with available mutation counts and predicted neoantigen counts were included. There was no significant difference in neoantigen count between low and high grades (median 50.50 vs. 62.50, p=0.84). However, there was a trend for differential numbers in the neoantigen count between type 1 and type 2 (median 29 vs. 66.50, p=0.07). No notable differences were detected in immune landscapes of low vs. high grade and type 1 vs. type 2. Conclusions: Our study is the first to describe the neoantigen and immune landscape of SOC. There were no significant differences in the immune landscape between the subtypes. It seems that molecular subtyping is more related to neoantigen differences than histologic subtyping. It is likely that the neoantigen differences are not defined by the histologic grade but rather by molecular trait. The immunologic characteristics of EMT low and high SOCNumber of ptientsNeoantigen countp-valueMutation countp-valueCytolytic scorep-valuePD-L1 expressionp-valueLow grade1250.500.84700.8757.120.4812.340.28High grade8062.5085.571.0919.66Type 117290.07114.60.98125.10.7824.940.77Type 222066.50115.3119.526.3High grade(TP53 wild type)744.000.06620.08163.20.0629.770.5High grade(TP53 mutated)7364.0086110.126.47TCGA cohort provided the data of low(GB, G1, G2) and high(G3, G4) grade SOCsType 1: Defined as mutations in KRAS, BRAF, PTEN, PIK3CA, CTNNB1 and ARID1A irrespective of histologic gradeType 2: Defined as mutation in TP53 irrespective of histologic gradeThe samples that had intersecting mutations were excluded in type 1 and type 2.The cytolytic activity score was defined as a geometric mean of mRNA expression of perforin and granzyme. Citation Format: Won Kyung Hur, Jin Young Hwang, Leeseul Kim, Myungwoo Nam, William H. Bae, Yoonhee Choi, Yeun Ho Lee, William Cheng, Heayoon S. Cho, Emma Yu, Chan Mi Jung, Eugene Kim, Christmann Low, Victor Wang, Jeff Chuang, Young Kwang Chae. The neoantigen and immune landscape of low and high grade serous ovarian cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 453.

Hyperprogression is a severe adverse event usually reported in immunogenic cancers such as non-small cell lung cancer (NSCLC) and melanoma after immunotherapy. Currently, there are no reported cases of hyperprogression seen in thyroid cancer. Here, we present the first case of follicular thyroid cancer patient with PDL-1 A 53-year old male with stage IV follicular thyroid cancer with multiple skeletal metastases, including left fifth rib, T1, T4, T5 vertebral body, was treated with Lenvatinib on 1/2018 and held on 12/2018 due to esophagus dilation. No targetable mutations were detected with molecular studies and PD-L1 was not expressed on the tumor. The patient received 1 cycle of nivolumab (3mg/kg) and ipilimumab (1mg/kg) on 7/27/2020, but could not continue the treatment due to neurologic deterioration and progression on follow-up CT. We defined hyperprogression per the criteria proposed by Lo Russo et al (2018), which defined it as meeting at least 3 out of 5 following criteria: TTF Before the initiation of immunotherapy, a CT chest scan revealed no target lesion, thus the sum of target lesions major diameters reported as 0. At baseline, the patient complained of numbness and tingling in the upper extremities. Follow-up imaging studies three weeks after the initiation of immunotherapy showed a 24.4 x 18.4 mm right hilar lymph node metastasis and a 6.7 x 4.2 cm right shoulder heterogeneous mass was reported on CT chest scan and scapula MRI, respectively. Along with progression of the disease, the patient developed rapid neurologic deteriorations including diminished bilateral hand grip and positive Romberg's test. The sum of target lesion major diameters was 85.4 mm, TTF This is the first case report of hyperprogression in follicular thyroid cancer, which is less immunogenic compared to NSCLC and melanoma. The underlying mechanism of hyperprogression and its association with immunotherapy remains unclear. Further research on potential risks of hyperprogression in less immunogenic cancer such as thyroid cancer is warranted. Citation Format: Yeun Ho Lee, Leeseul Kim, Myungwoo Nam, William Cheng, Won Kyung Hur, Jin Young Hwang, Yoonhee Choi, William H Bae, Eugene Kim, Heayoon Shauna Cho, Emma Yu, Chan Mi Jung, Christmann Low, Elena Vagia, Young Kwang Chae. Hyperprogression in follicular thyroid cancer treated with combination immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 519.

TP53-mutation is a poor prognostic marker for uterine corpus endometrial carcinoma (UCEC). TGF-β is known to promote tumor progression via immune suppression, particularly NK and T cell-mediated cytotoxicity, in the tumor microenvironment. We aimed to analyze the impact of TGF-β signaling pathway-related gene mutation on the immune landscape and survival outcomes in TP53-mutated UCEC patients. cBioPortal was queried to obtain the UCEC The Cancer Genome Atlas cohort data (TCGA, 529 patients). The neoantigen counts were predicted using the CloudNeo pipeline. Survival outcomes were compared in the TGF-β signaling pathway-related gene mutated group, which were defined as genetic variances in TGFBR1, TGFBR2, ACVR2A, ACVR1B, SMAD2, SMAD3, or SMAD4, and the TGF-β signaling pathway-related gene non-mutated group. The cytolytic activity score was defined as a geometric mean of mRNA expression of perforin and granzyme. The duration of overall survival and disease-free survival were also obtained from cBioPortal. Out of the 529 UCEC patients, 192(36.3%) cancer tissues with TP53 mutations were analyzed for this study. 44 patients (22.9%) had more than one mutation in their TGF-β signaling pathway-related genes. TGF-β signaling pathway-related gene mutated group, when compared to a non-mutated group, was associated with significantly increased neoantigen counts (519.3 vs. 20.34 ; p Citation Format: William H. Bae, Jin Young Hwang, Won Kyung Hur, Myungwoo Nam, Yoonhee Choi, Leeseul Kim, Yeun Ho Lee, William Cheng, Eugene Kim, Emma Yu, Chan Mi Jung, Jeff Chuang, Victor Wang, Young Kwang Chae. TGF-β signaling pathway-related gene mutations are associated with increased neoantigen counts, enhanced cytolytic activity, and improved survival outcomes in TP53-mutated endometrial carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 452.

Early recognition of immune-related adverse events (irAEs) of immunotherapy is important. Circulating proteome reflects host response to diseases and is being explored as a marker for response to immunotherapy. We used a serum-based proteomics test, Primary Immune Response (PIR), to explore the associations between developing irAEs and immunotherapy in non-small cell lung cancer (NSCLC) patients. Data of 38 consented NSCLC patients with baseline PIR test done within one week prior to the start of immunotherapy were collected. Samples were grouped into either sensitive or intermediate/resistant (not sensitive) by PIR classification. We analyzed the durations from the immunotherapy initiation to the first episode of irAE, each individual irAE, and each irAE above grade 1 using log-rank test. IrAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Among the 38 NSCLC patients, 21 patients (55%) experienced one or more irAEs. The total number of irAEs was 33 with the majority classified as either grade 1 (n=18, 55%) or grade 2 (n=11, 33%) (Table 1). PIR-sensitive group showed longer irAE free period with the median ‘Time to first irAE' being 54 weeks compared to 9.5 weeks in PIR-not sensitive (p=0.22, HR=0.56, 95% CI=0.24-1.34). The median ‘Time to each irAE' were 45 weeks and 12 weeks in PIR-sensitive and PIR-not sensitive, respectively (p=0.1, HR=0.55, 95% CI=0.28-1.1). The median ‘Time to each irAE above grade 1' demonstrated similar results with less differences between the two groups with median values of 54 weeks and 30 weeks in PIR-sensitive and PIR-not sensitive, respectively (p=0.28, HR=0.57, 95% CI=0.21-1.56). Our results demonstrated a trend that PIR-sensitive patients are more likely to tolerate immunotherapy longer without developing irAEs. It implies the potential value of the baseline PIR test in predicting the development of irAEs and selecting subsets of patients who need close monitoring with immunotherapy. Distribution of irAEs by PIR classificationVariablesSensitiveNot-sensitiveTotal number of patients, n1325Patients without irAE, n (%)7 (54%)10 (40%)Patients with irAE, n (%)6 (46%)15 (60%)Total number of irAEs, n1023Grade 1, n (%)5 (50%)13 (57%)Grade 2, n (%)5 (50%)6 (26%)Grade 3, n (%)02 (8%)Grade 4, n (%)01 (4%)Grade 5, n (%)01 (4%) Citation Format: Myungwoo Nam, Leeseul Kim, William Cheng, William H. Bae, Jin Young Hwang, Yoonhee Choi, Yeun Ho Lee, Won Kyung Hur, Chan Mi Jung, Heayoon S. Cho, Young Kwang Chae. Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 520.

Purpose: The growth velocity in patients with central precocious puberty during treatment cannot be predicted. There is a positive correlation in growth among the long bones of the body and the length of the femur and tibia may determine individual height. We want to determine whether the second metacarpal bone can be used as a predictive index for growth velocity during gonadotropin-releasing hormone (GnRH) agonist treatment. Methods: Thirty-four female children who were diagnosed with precocious puberty at our clinic and treated with GnRH agonist for about 1 year were included in this study. Patients who had growth-related disease, such as growth hormone deficiency and thyroid diseases were excluded. We reviewed their medical records retrospectively. We measured their height and the second metacarpal length from the X-ray film (left hand Anterior-Posterior at the time of their diagnosis and about a year after their GnRH agonist treatment. Results: The age of the subjects was 8.5±0.6 years. The growth velocity during treatment was 4.9±1.2 cm/yr. There was a positive correlation between height and the second metacarpal length at diagnosis (P = 0.000, r = 0.666) and at one year after treatment (P = 0.000, r = 0.654). There was no correlation between the second metacarpal length at diagnosis and growth velocity during treatment for 1 year. Conclusion: We could not find the correlation between the second metacarpal length and growth velocity during GnRH agonist treatment for 1 year. However, the second metacarpal length showed a positive correlation with height before and after treatment. Therefore further study should be done to discovering the mechanisms working during GnRH agonist treatment including bone age, midparental height and so on.